(Q38151456)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Micronutrient status in phenylketonuria (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

M Robert

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

M van Rijn

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

K Ahring

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

A Bélanger-Quintana

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

A MacDonald

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

K Dokoupil

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

H Gokmen Ozel

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

A M Lammardo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

P Goyens

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

F Feillet

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

19 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

Molecular Genetics and Metabolism

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

110 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

S6-17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

Identification of an intestinal heme transporter

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Bioavailability of minerals and trace elements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Improving the bioavailability of nutrients in plant foods at the household level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Vitamin B12 deficiency in adolescents and young adults with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Spastic paraparesis after anaesthesia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Cognitive functions and the antioxidant system in phenylketonuric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Poor zinc and selenium status in phenylketonuric children and adolescents in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Long-term efficacy of 'ready-to-drink' protein substitute in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Long-term compliance with a novel vitamin and mineral supplement in older people with PKU.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Vitamin B12 deficiency in an adult phenylketonuric patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Increased risk of vitamin B12 deficiency in patients with phenylketonuria on an unrestricted or relaxed diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Vitamin B12 deficiency and phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Vitamin B12 and vitamin B6 supplementation is needed among adults with phenylketonuria (PKU)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Serum vitamin B12 concentrations within reference values do not exclude functional vitamin B12 deficiency in PKU patients of various ages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Acceptability of a new modular protein substitute for the dietary treatment of phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Nutrition in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Main issues in micronutrient supplementation in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Pre- and postfortification intake of folate and risk of colorectal cancer in a large prospective cohort study in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Folic acid and cancer--where are we today?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Serum-selenium concentrations in patients with maple-syrup-urine disease and phenylketonuria under dieto-therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Trace elements nutriture in hyperphenylalaninemic patients. Long-term follow up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Trace element nutrition status and dietary intake of children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Potentially life-threatening cardiac dysrhythmia in a child with selenium deficiency and phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

The brain selenoproteome: priorities in the hierarchy and different levels of selenium homeostasis in the brain of selenium-deficient rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Deficiency of selenium enhances the K+-induced release of dopamine in the striatum of mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Dietary selenium and major depression: a nested case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

PKU: High plasma phenylalanine concentrations are associated with increased prevalence of mood swings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

The choice of biomarkers determines the selenium status in young German vegans and vegetarians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Selenium bioavailability: current knowledge and future research requirements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Selenium and iodine intakes and status in New Zealand and Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Effectiveness of selenium supplements in a low-selenium area of China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Micronutrients in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Evaluation of nutritional status and pathophysiology of growth retardation in patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Methods of assessment of zinc status in humans: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Bioavailability in infants of iron from infant cereals: effect of dephytinization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Iron bioavailability and dietary reference values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

BH(4) therapy impacts the nutrition status and intake in children with phenylketonuria: 2-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Fractures and phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Bone mineral status in children with phenylketonuria--relationship to nutritional intake and phenylalanine control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Decreased bone mineral density in children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Bone metabolism and the muscle-bone relationship in children, adolescents and young adults with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Bone development in children and adolescents with PKU.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Relationships between lumbar bone mineral density and biochemical parameters in phenylketonuria patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Peak bone mass in patients with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Cross-sectional study of bone metabolism with nutrition in adult classical phenylketonuric patients diagnosed by neonatal screening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Fatty acid profile in patients with phenylketonuria and its relationship with bone mineral density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Impact of metabolic control on bone quality in phenylketonuria and mild hyperphenylalaninemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Lipophilic antioxidants in patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Effect of diet on plasma total antioxidant status in phenylketonuric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Impact of lipophilic antioxidants and level of antibodies against oxidized low-density lipoprotein in Polish children with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Teratogen update: vitamin A congeners

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Vitamin B-6 status of school-aged patients with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Oxidative stress induced by phenylketonuria in the rat: Prevention by melatonin, vitamin E, and vitamin C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Oxidative stress in a phenylketonuria animal model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Oxidative stress in patients with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Investigation of oxidative stress parameters in treated phenylketonuric patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Effect of short- and long-term exposition to high phenylalanine blood levels on oxidative damage in phenylketonuric patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Oxidative stress in phenylketonuria: what is the evidence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Oxidative stress in phenylketonuria: future directions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

The oxidative stress of zinc deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Antioxidant status in hyperphenylalaninemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Antioxidant and thyroid hormone status in selenium-deficient phenylketonuric and hyperphenylalaninemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Selenium, glutathione peroxidase (GSH-Px) and lipid peroxidation products before and after selenium supplementation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

The effect of diet on total antioxidant status, ceruloplasmin, transferrin and ferritin serum levels in phenylketonuric children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Low total antioxidant status is implicated with high 8-hydroxy-2-deoxyguanosine serum concentrations in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Antioxidant treatment strategies for hyperphenylalaninemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Evidence that l-Carnitine and Selenium Supplementation Reduces Oxidative Stress in Phenylketonuric Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Serum selenium levels in individuals on PKU diets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Selenium status in infants and children with phenylketonuria and in maternal phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

A longitudinal study of antioxidant status in phenylketonuric patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Plasma zinc, copper, and erythrocyte superoxide dismutase in children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

The association of serum lipids, lipoproteins and apolipoproteins with selected trace elements and minerals in phenylketonuric patients on diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Inadequate iron availability as a possible cause of low serum carnitine concentrations in patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Iron and protein sufficiency and red cell indices in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Iron status of children with phenylketonuria undergoing nutrition therapy assessed by transferrin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Haematological findings in children with inborn errors of metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Experimental evidence that phenylalanine is strongly associated to oxidative stress in adolescents and adults with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

L-carnitine blood levels and oxidative stress in treated phenylketonuric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Oxidative stress in phenylketonuric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

Coenzyme Q10 in phenylketonuria and mevalonic aciduria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.09.009

10.1016/J.YMGME.2013.09.009

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24113686%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference